Merck & Co (NY:MRK)

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

Wondering what's happening in today's after-hours session with S&P500 stocks? Stay tuned for the latest updates on movers and shakers.

Topics Artificial Intelligence Economy Intellectual Property

Top gainers and losers in the S&P500 index during Monday's after-hours session. ↗

December 29, 2025

Via Chartmill

The Price of Prosperity: Navigating the S&P 500’s Historic Valuation Peak as 2026 Dawns

December 29, 2025

As the final trading days of 2025 draw to a close, the financial world finds itself standing on a high-altitude plateau that few predicted and many fear. The S&P 500 (INDEXSP: .INX) enters 2026 trading...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Topics Artificial Intelligence Bonds Earnings

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a...

Topics Intellectual Property

The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit

December 26, 2025

Merck exemplifies quality investing with high ROIC, strong cash flow, and a solid balance sheet, making it a durable long-term healthcare investment candidate.

Merck & Co. Inc. (NYSE:MRK) Emerges as a Top Quality Investing Candidate ↗

December 26, 2025

Via Chartmill

Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom

December 25, 2025

NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of...

As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a...

Topics Economy Intellectual Property

Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026

December 25, 2025

The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies

Topics Artificial Intelligence Economy Intellectual Property

December 25, 2025

Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been...

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Topics Economy Intellectual Property

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025

Topics Artificial Intelligence Economy Intellectual Property

December 24, 2025

As the curtain closes on 2025, the healthcare sector has emerged as a landscape of stark contrasts. While traditional pharmaceutical giants have grappled with the implementation of the Medicare Part D...

Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery

Topics Bonds Earnings World Trade

December 24, 2025

As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based...

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

Topics Initial Public Offering

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax...

Topics Artificial Intelligence Economy Intellectual Property

Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition

December 24, 2025

In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge...

Topics Economy

Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring

December 24, 2025

Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025.

Topics Intellectual Property

Top 5 US Healthcare Stocks By Market Value ↗

December 24, 2025

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

Topics Government

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency

Topics Economy

SCHD vs. NOBL: Different Paths to Dividend Stability ↗

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Topics ETFs

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Topics ETFs Economy Intellectual Property

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...

Topics Economy Intellectual Property

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

This year has been one to forget for these pharmaceutical giants.

Topics Earnings Initial Public Offering Intellectual Property

Better Buy in 2026: Pfizer or Merck? ↗

December 19, 2025

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

Topics Intellectual Property

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Merck (MRK) offers a strong 3.43% dividend yield, backed by a history of increases, high profitability, and solid financial health for durable income.

Topics Government World Trade

Merck & Co. Inc. (NYSE:MRK) Stands Out as a Durable Dividend Stock ↗

December 19, 2025

Via Chartmill

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

Topics Economy Government

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

As the calendar turns toward 2026, the exuberant "AI-everything" rally that defined much of 2024 and 2025 is facing a sobering reality check. With the Federal Reserve entering a delicate transition...

Topics Artificial Intelligence ETFs Economy

The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'

December 18, 2025

Merck Scores FDA Fast-Track Review For Key Cholesterol And Cancer Drugs With Multibillion-Dollar Potential: Report ↗

Topics Artificial Intelligence Economy World Trade

December 17, 2025

While one of the drugs reportedly slated for fast-track review is the cholesterol pill Enlicitide decanoate, the other is its cancer therapy Sacituzumab tirumotecan.